Study Finds 1 in 3 Tanzanian Newborns Infected with Multi‑Drug‑Resistant Bacteria
A six‑month study at Bugando Medical Centre in Mwanza identified 58 bloodstream infections among newborns, 34 of which were caused by bacteria resistant to three or more antibiotics. The data were collected between January and June 2024 and analyzed by a team of Tanzanian and international microbiologists. These infections are harder to treat, leading to longer hospital stays and higher mortality. The findings signal a public‑health challenge that could spread beyond the neonatal ward.
What the Study Revealed
The research, led by Dr. Asha Mkwawa and published in the Tanzanian Journal of Clinical Microbiology, examined all neonatal admissions to Bugando Medical Centre’s intensive care unit from 1 January to 30 June 2024. During that period, 212 newborns were admitted, and 58 (27%) developed laboratory‑confirmed sepsis. Of those 58 cases, 34 (58%) were caused by bacteria classified as multi‑drug‑resistant (MDR) by the Clinical and Laboratory Standards Institute criteria. The most common pathogens were Klebsiella pneumoniae (45% of MDR isolates) and Escherichia coli (30%). Notably, 22 of the Klebsiella strains were resistant to carbapenems, the last‑line antibiotics traditionally reserved for severe infections. The study also recorded a median time‑to‑appropriate therapy of 48 hours for MDR cases, compared with 12 hours for susceptible infections. The mortality rate among newborns with MDR sepsis was 28%, nearly double the 15% observed in non‑MDR cases. Researchers traced the resistant strains to a combination of over‑use of broad‑spectrum antibiotics in the ward and limited infection‑control resources. The full report is available through the Bugando Medical Centre repository.
Why the Findings Matter
First, the surge in MDR infections jeopardizes Tanzania’s progress toward the Sustainable Development Goal target of reducing under‑five mortality to at least 25 per 1,000 live births. Neonatal sepsis already accounts for roughly 30% of infant deaths nationwide; adding drug resistance inflates that risk. Second, the presence of carbapenem‑resistant Klebsiella signals that even the most powerful antibiotics are losing efficacy. If these organisms spread to community hospitals, treatment options for common infections could vanish, forcing clinicians to rely on older, more toxic drugs. Third, families bear the financial burden of prolonged hospitalisation and expensive, often unavailable, second‑line antibiotics. In Mwanza, the average out‑of‑pocket cost for a neonatal sepsis episode rose from 150,000 Tanzanian shillings in 2022 to 260,000 shillings in 2024, according to the hospital’s finance office. Fourth, the study highlights gaps in laboratory capacity. Only 40% of suspected sepsis cases received a blood culture before antibiotics were started, limiting early detection of resistance patterns. Strengthening microbiology services could enable targeted therapy, reducing both mortality and drug waste. Finally, the findings echo a global trend: the World Health Organization has warned that antimicrobial resistance could cause 10 million deaths annually by 2050 if unchecked. Tanzania’s newborns are now on the front line of that forecast.
“Dr. Asha Mkwawa told reporters that the rise in resistant infections could undo decades of progress in neonatal care, urging immediate investment in infection‑control training and rapid diagnostic tools.”
Unanswered Questions
The study leaves several critical gaps. It does not clarify how many of the MDR strains originated from the hospital environment versus community transmission, a distinction that would shape containment strategies. Genetic sequencing of the bacteria was limited to a subset of isolates, so the prevalence of specific resistance genes, such as NDM‑1 or OXA‑48, remains uncertain. Moreover, the research did not assess maternal colonisation, which could be a source of neonatal infection during delivery. The impact of current antibiotic stewardship policies at Bugando is also unclear; the hospital introduced a new prescribing protocol in March 2024, but the study period overlaps with its rollout, making it difficult to isolate its effect. Finally, the long‑term outcomes for survivors of MDR sepsis—such as neurodevelopmental delays or chronic health issues—were not tracked, leaving families and policymakers without a full picture of the burden.
Key Takeaways
- One‑third of newborns with sepsis at Bugando were infected by multi‑drug‑resistant bacteria.
- Carbapenem‑resistant Klebsiella pneumoniae accounted for 22 of the 34 MDR cases.
- Mortality among MDR‑infected newborns was 28%, nearly double that of non‑MDR infections.
- Limited blood‑culture capacity and delayed therapy prolong hospital stays and increase costs.
What to Watch in the Coming Days
Health officials in the Mwanza region plan to convene an emergency task force on 2 October 2024, bringing together the Ministry of Health, the Tanzania Food and Drugs Authority, and international partners like the WHO. Watch for the task force’s recommendations on restricting carbapenem use in neonatal wards and on scaling up point‑of‑care PCR testing for resistance genes. In addition, Bugando Medical Centre announced a pilot program on 3 October to install an automated blood‑culture system, aiming to cut time‑to‑diagnosis from 48 hours to under 12 hours. Follow the Ministry’s weekly bulletins for any changes to national antibiotic guidelines, especially any new restrictions on third‑generation cephalosporins. Finally, monitor reports from the East African Public Health Laboratory Network for any alerts of MDR outbreaks in neighboring districts, which could signal a broader regional spread.
The first documented case of carbapenem‑resistant Enterobacteriaceae in Tanzania was reported in 2017 by the WHO Global Antimicrobial Resistance Surveillance System.
The Bugando study paints a stark picture: newborns in Tanzania are confronting infections that outpace the drugs meant to cure them. Yet the report also offers a roadmap—enhanced diagnostics, stricter antibiotic stewardship, and stronger infection‑control measures—that could stem the tide. Families, clinicians, and policymakers must act together, because the health of the nation’s youngest citizens depends on the choices made in the next few weeks.
